Fever-Tree Profits Rise 9% as US Sales Momentum Accelerates

Key Facts

1Fever-Tree's adjusted EBITDA rose 9% to £20.1 million in the first half of the year.

2Brand revenue grew 8% at constant currency to £183.6 million, driven by the partnership with Molson Coors.

Amid a strategic push by British beverage firms to capture larger shares of global markets, Fever-Tree has demonstrated significant financial resilience. According to reports, the company's adjusted EBITDA rose 9% to £20.1 million in the first half of the year. Brand revenue also grew by 8% at constant currency to reach £183.6 million, underscoring the success of its international expansion efforts.

This positive performance was primarily driven by accelerating sales in the US market, where the partnership with Molson Coors helped secure record retail market shares. Per analyst data, US revenue increased 11% at constant currency to £66.9 million, while the UK business returned to growth with a 3% increase. This growth comes as market data indicates mixed performance across the broader global consumer sector.

Looking ahead, updated price levels for FEVR were unavailable at the close of September 10, 2026, necessitating a focus on liquidity levels at the next market open. Investors are also monitoring upcoming economic catalysts, including the Canadian Balance of Trade figures, which may influence sentiment in North American markets where the company is seeing double-digit underlying growth.